News

As any scientist knows, a lot can go wrong during an experiment. Once you have your final samples and you’re ready for analysis, that’s not the time to be taking any chances.

Businesses and organizations have similar reasons for outsourcing non-core functions, yet some functions are more crucial than others.

Running a histology lab is going to involve a lot of research material that could easily become damaged if you're running out of space.

When the FDA Animal Rule, or Animal Efficacy Rule, became law in 2002, it created a pathway for assessing the safety and efficacy of drugs and biological products for “serious or life-threatening conditions caused by exposure to lethal or permanently disabling substances” when human clinical trials are not ethical or feasible.

As your histology lab staff know well, doing a necropsy is extremely complex, and it requires exacting detail to evaluate animal tissue.

When you're in the middle of research or trying to get a product approved by the FDA, histopathology is what's going to help you every step of the way.

Stem cell therapy has advanced significantly over the last decade. In particular, it has shown promising results in regenerating cells in certain tissues of critical importance for life but limited natural ability to regenerate, including the central nervous system and myocardium.

Time is of the essence in the realm of contract research organizations, academic institutions, pharma and biotech -- but so are accuracy and affordability.

Are you considering the addition of immunohistochemistry (IHC) to your preclinical toxicology study design? IHC integrates molecular pathology and traditional histopathology to allow the visualization of test compounds or cellular targets in situ.

You may depend heavily upon histopathology and the reports that follow. Regardless of whether you are a clinic, a contract research organization, a pharmaceutical company, or anyone else, the information that you get from histopathology can be critical.